LMR Partners LLP bought a new position in shares of Insulet Co. (NASDAQ:PODD – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 15,111 shares of the medical instruments supplier’s stock, valued at approximately $3,517,000.
Several other large investors have also added to or reduced their stakes in the business. Wedmont Private Capital grew its stake in Insulet by 3.5% during the third quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier’s stock worth $326,000 after purchasing an additional 48 shares during the period. OVERSEA CHINESE BANKING Corp Ltd grew its stake in Insulet by 4.7% during the third quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 1,076 shares of the medical instruments supplier’s stock worth $250,000 after purchasing an additional 48 shares during the period. Blue Trust Inc. grew its stake in Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in Insulet by 1.1% during the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,265 shares of the medical instruments supplier’s stock worth $1,264,000 after purchasing an additional 66 shares during the period. Finally, Greenleaf Trust boosted its holdings in Insulet by 4.2% in the third quarter. Greenleaf Trust now owns 1,783 shares of the medical instruments supplier’s stock worth $415,000 after acquiring an additional 72 shares in the last quarter.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on PODD. Piper Sandler increased their price target on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. Sanford C. Bernstein began coverage on Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target on the stock. BTIG Research increased their price target on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Morgan Stanley increased their price target on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Finally, Citigroup increased their price target on Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a report on Tuesday, October 1st. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and an average price target of $253.27.
Insulet Stock Performance
Shares of Insulet stock opened at $260.68 on Tuesday. The business’s fifty day simple moving average is $238.60 and its 200 day simple moving average is $208.60. The firm has a market capitalization of $18.28 billion, a P/E ratio of 44.64, a price-to-earnings-growth ratio of 3.98 and a beta of 1.22. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.40. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.
Insulet Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
Read More
- Five stocks we like better than Insulet
- How to Use Stock Screeners to Find Stocks
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Applied Materials Market Capitulates: Now is the Time to Buy
- Most active stocks: Dollar volume vs share volume
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.